The challenge we choose to face

Cardiovascular diseases are the leading cause of mortality globally, responsible for almost 18 million deaths per year.

Today, diagnostics are often inaccurate and time-consuming. General practitioners still rely on single biochemical markers such as cholesterol and blood pressure, which can fail to recognise the signs of increased risk of suffering a major cardiovascular event. In turn, late diagnosis and inadequate prognosis decrease the chances for successful intervention with primary cardiovascular preventive measures, ultimately creating financial and psychological strain for the patient, their families and their doctors.

Our solution

We offer a whole blood screening test using RNA Sequencing and Artificial Intelligence to detect complex diseases, including cardiovascular disorders and cancer.

Rather than searching for a single molecule that identifies a cardiovascular risk, our test identifies molecular variances in the blood that indicate an increased risk of a cardiovascular event.  Imagine measuring all blood RNA changes that a cardiac risk factor may induce at the same time: A powerful, deep and accurate superbiomarker.

This gives MultiplAI the power to:

• Accuracy: our approach brings precision medicine to cardiovascular and other complex diseases as has been done with DNA for cancer
• Simplified results: less confusing or ambiguous results when compared to existing cardiac screening methods
• Timely intervention: allows more timely and successful intervention to prevent heart attack or stroke based on evidence not previously seen
• Universal access: our use of a simple whole blood biopsy and the exponentially decreasing costs of sequencing makes CVD screening affordable and widely accessible to virtually anyone in the world
• Improved treatment efficacy assessment: provides the ability to assess and adjust treatment regimens with more confidence